Home / Business and Economy / Lilly Nears $2B Diabetes Drug Deal with AI Firm

Lilly Nears $2B Diabetes Drug Deal with AI Firm

29 Mar

Summary

Eli Lilly is reportedly close to a $2 billion deal.
The agreement is with Insilico Medicine for a diabetes drug.
Insilico Medicine utilizes artificial intelligence for drug discovery.

Lilly Nears $2B Diabetes Drug Deal with AI Firm

Eli Lilly is reportedly on the verge of signing a significant deal valued at approximately $2 billion. The agreement would grant the pharmaceutical giant exclusive rights to market a GLP-1 drug specifically designed for diabetes treatment. The drug originates from Insilico Medicine, a biotech company listed in Hong Kong. Insilico Medicine is recognized for its innovative approach, employing artificial intelligence to accelerate the discovery of new medications. This potential transaction underscores the increasing integration of AI technologies within the pharmaceutical sector. The reported deal signals a strategic move by Eli Lilly to bolster its portfolio in the competitive diabetes drug market.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.